Good and Bad Drugs
The use of Nevirapine while pregnant is generally safe. Wide usage of such
antiretroviral drug aims to decrease or eliminate the chance of the HIV transmission to child.
This drug is widely distributed in London and United States for those who are pregnant and
HIV patient. The use of Nevirapine while pregnant was considered normally safe and is
clinically proven in giving a halt in the transmission of HIV to the fetus. However minor
reports of side effects and some cases of deaths were presented.
The potential side effects of Nevirapine are usually skin related. The most common
among these problems are rashes, herpes, cholestasis and erythema nodosum. The cases of
which rashes were reported were relatively small. In a certain study conducted by the British
HIV Association, only 6.4 % of the correspondents reported side effects regarding rashes.
Other side effects that were reported were hepatic failure, toxicity and even death. These
reports however were some of the isolated cases.
Safety of Nevirapine to pregnant women was studied and numerous accounts say that
it is not dangerous. One of this is the work published by the British HIV association this year,
2007. According to the study, only 29.4% of the subjects showed adverse effect of
Nevirapine. This was relatively low compared to the remaining difference. This result as well
as other study nearly suggests one thing. This is the fact that generally, women that are
pregnant and have HIV can continue her drug cocktail.
With regards to what I cited above, it can be generalized that it is not dangerous to
take Nevirapine while the woman is pregnant. The minimal side effect of the Nevirapine is
nothing compared to the benefit that the drug will give to both the parent and child.
Antiretroviral therapy in relation to diabetes has a large impact to the wellness of the
subject. It is hazardous to take antiretroviral therapy while the subject has diabetes because it
was well known that the insulin is well resisted with the antiretroviral therapy. In such case
the diabetes treatment will be disrupted and total body balance and will cause a net negative
Reports regarding the abnormalities in the glucose and lipid metabolism of patients
that were exposed to several combination of antiretroviral were present. The danger at risk
upon the resistance to glucose is the lipodystrophy syndrome. The result of the disruption of
the glucose metabolism will lead to other dreadful diseases such as coronary heart disease
Some individuals subjected to the antiretroviral therapy was observed to have a
“buffalo hum” this is a dorsocervical fat deposit which was observed that persons having this
fat deposit is closely related for having diabetes. One of the most hazardous after effect of
insulin resistance is the cognitive impairment. This is also linked to some cases like the
Given these sets of consequences, it is a no to use antiretroviral therapy because the
healing that can be made by the therapy cannot compensate for the possible loss of the totally
of the body. Dreadful diseases seem to come from the insulin resistance catered by the
antiretroviral therapy so it would not be a wise choice to involve an individual with diabetes
and HIV into an antiretroviral therapy. The probable cure for the HIV will be doorway to an
array of diseases which is unfavorable to the patient. On these grounds, I do not recommend
antiretroviral therapy while the individual has diabetes.
Black Synergy. September 6, 2007 <http://www.epigee.org/aidsdrugs.html>
Epigee womens on health, Anti-AIDS Drugs and Pregnancy September 6,
2007<http://www.epigee.org/aidsdrugs.html>
Ingenta connect. Safety of nevirapine in pregnancy. September 6, 2007
Mcneil. New York times. September 6, 2007
Poly clayden. HIV Treatment Bulletin Volume 5 Number 3 April 2004. I-Base September 6 ,
2007<http://www.i-base.info/pub/htb/v5/htb5-3/Nevirapine.html>
U. Natarajan et al, Medscape today. September 6,
The 17-Month Extension applies to students in STEM (Science, Technology, Engineering, and Math) fields. Please read and complete the following form and International Student, Scholar, and Immigration Services (ISSIS) will process your application accordingly. IMPORTANT: *Your employer for the 17-Month Extension MUST be a participant in E-Verify. Go to http://www.dhs.gov/ximgtn/programs/
symbol order were fil ed out and if these participation terms and conditions as well as the business terms and conditions and 2.2 Due to the fact that participation is 1 These terms and conditions shall apply limited for eco events, registrations are (hereinafter „participant“) to eco Service receipt. As long as the number of tickets GmbH events –- (hereinafter „eco“). requested